Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib.
Jiménez-Fonseca P, Martín MN, Carmona-Bayonas A, Calvo A, Fernández-Mateos J, Redrado M, Capdevila J, Lago NM, Lacasta A, Muñarriz J, Segura Á, Fuster J, Barón F, Llanos M, Serrano R, Castillo A, Cruz Hernández JJ, Grande E. Jiménez-Fonseca P, et al. Among authors: llanos m. Oncotarget. 2018 Dec 11;9(97):36894-36905. doi: 10.18632/oncotarget.26380. eCollection 2018 Dec 11. Oncotarget. 2018. PMID: 30651923 Free PMC article.
Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P, Carmona-Bayonas A, Martín-Pérez E, Crespo G, Serrano R, Llanos M, Villabona C, García-Carbonero R, Aller J, Capdevila J, Grande E; Spanish Neuroendocrine Tumor Group (GETNE). Jiménez-Fonseca P, et al. Among authors: llanos m. Cancer Metastasis Rev. 2015 Sep;34(3):381-400. doi: 10.1007/s10555-015-9573-1. Cancer Metastasis Rev. 2015. PMID: 26245646 Review.
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.
Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, Barriuso J, Castaño Á, Benavent M, Alonso V, Riesco-Martínez MDC, Alonso-Gordoa T, Custodio A, Sánchez Cánovas M, Hernando Cubero J, López C, Lacasta A, Fernández Montes A, Marazuela M, Crespo G, Escudero P, Diaz JÁ, Feliciangeli E, Gallego J, Llanos M, Segura Á, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle JW, García-Carbonero R. Carmona-Bayonas A, et al. Among authors: llanos m. J Clin Oncol. 2019 Oct 1;37(28):2571-2580. doi: 10.1200/JCO.19.00980. Epub 2019 Aug 7. J Clin Oncol. 2019. PMID: 31390276 Free PMC article.
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castaño A, Benavent M, Alonso V, Riesco MDC, Alonso-Gordoa T, Custodio A, Sanchez Canovas M, Hernando J, López C, La Casta A, Fernandez Montes A, Marazuela M, Crespo G, Diaz JA, Feliciangeli E, Gallego J, Llanos M, Segura A, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle J, Garcia-Carbonero R. Jimenez-Fonseca P, et al. Among authors: llanos m. Neuroendocrinology. 2022;112(1):88-100. doi: 10.1159/000514808. Epub 2021 Jan 28. Neuroendocrinology. 2022. PMID: 33508849
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R. Nuñez-Valdovinos B, et al. Among authors: llanos m. Oncologist. 2018 Apr;23(4):422-432. doi: 10.1634/theoncologist.2017-0364. Epub 2018 Jan 12. Oncologist. 2018. PMID: 29330208 Free PMC article.
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.
Viúdez A, Crespo G, Gómez Dorronsoro ML, Arozarena I, Marín-Méndez JJ, Custodio A, Benavent M, Goñi S, García-Paredes B, Hernando J, Durantez M, Alonso V, Riesco MDC, López C, Jiménez-Fonseca P, San Vicente BL, González-Borja I, Sevilla I, Hernández-Garcia I, Carmona-Bayonas A, Capdevila J, Pérez-Sanz J, García-Carbonero R, Pérez-Ricarte L, Llanos M, Vera R, De Jesús Acosta A. Viúdez A, et al. Among authors: llanos m. Pancreatology. 2021 Jan;21(1):215-223. doi: 10.1016/j.pan.2020.12.009. Epub 2020 Dec 19. Pancreatology. 2021. PMID: 33358592
Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study.
Vallejo Casas JA, Sambo M, López López C, Durán-Poveda M, Rodríguez-Villanueva García J, Santos RJ, Llanos M, Navarro-González E, Aller J, Pubul V, Guadalix S, Crespo G, González C, Zafón C, Navarro M, Santamaría-Sandi J, Segura Á, Gajate P, Gómez-Balaguer M, Valdivia J, Puig-Domingo M, Galofré JC, Castelo B, Villanueva MJ, Argüelles I, Orcajo-Rincón L. Vallejo Casas JA, et al. Among authors: llanos m. Eur Thyroid J. 2022 Aug 11;11(5):e210111. doi: 10.1530/ETJ-21-0111. Print 2022 Oct 1. Eur Thyroid J. 2022. PMID: 35900793 Free PMC article.
Chemotherapy and radiotherapy in locally advanced cervical cancer.
Brunet J, Alonso C, Llanos M, Lacasta A, Fuentes J, Mendoza LA, Badia JM, Delgado E, Ojeda B. Brunet J, et al. Among authors: llanos m. Acta Oncol. 1995;34(7):941-4. doi: 10.3109/02841869509127209. Acta Oncol. 1995. PMID: 7492385 Clinical Trial.
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
Castellano D, Capdevila J, Sastre J, Alonso V, Llanos M, García-Carbonero R, Manzano Mozo JL, Sevilla I, Durán I, Salazar R. Castellano D, et al. Among authors: llanos m. Eur J Cancer. 2013 Dec;49(18):3780-7. doi: 10.1016/j.ejca.2013.06.042. Epub 2013 Sep 5. Eur J Cancer. 2013. PMID: 24012098 Clinical Trial.
150 results